One of the most routine uses of methylene blue in modern hospitals has nothing to do with mitochondria, oxygen, or the brain. Surgeons inject it into breast tissue and then follow the blue as it drains, because whichever lymph node turns blue first is the node that cancer would reach first. That node gets biopsied. The technique is well established and it works. It also carries a specific and well-documented complication that turns on one variable, which is how concentrated the dye was when it went in.
Key Takeaways
- Methylene blue is used as a lymphatic tracer in sentinel lymph node biopsy, most commonly in breast cancer surgery, because it visibly stains the first draining node.
- In a review of 401 procedures, overall technical success was 99.7 percent, so the method itself is reliable.
- Concentration and injection site drive the complication rate. Full-strength dye injected around the tumour had a 21 percent complication rate; dilute dye at 1.25 mg/mL injected under the areola had 2 percent.
- The characteristic complication is skin and fat necrosis at the injection site, reported in case series and occasionally progressing to gangrene requiring debridement.
- This is an injected surgical dye at surgical doses. It says nothing about the safety of oral methylene blue at supplement doses, and nothing about oral use causing skin damage.
Why a Dye Is Used at All
Sentinel lymph node biopsy exists to avoid removing more lymph nodes than necessary. Historically, breast cancer surgery involved clearing the axillary nodes wholesale, which carries a real risk of lymphoedema and shoulder dysfunction. The sentinel node concept replaces that with a question: if the cancer had spread through the lymphatics, which node would it have reached first? Find that node, examine it, and if it is clear the rest can usually be left alone.
To find it, something has to travel the same path the cancer would. That is either a radioactive tracer detected with a gamma probe, a visible dye the surgeon can see, or both together. Methylene blue is one of the dyes used for this, alongside isosulfan blue and patent blue V. Its advantages are availability, low cost, and a very low rate of the anaphylactic reactions that isosulfan blue is known for.
What the Concentration Data Show
The clearest picture of the risk profile comes from a retrospective review of 398 patients undergoing 401 sentinel node biopsy procedures, grouped by dye concentration and injection location. Overall technical success across all groups was 99.7 percent, so the technique itself is not in question[1].
The differences between the groups are where it gets useful. Full-strength dye injected peritumorally, meaning around the tumour itself, had the lowest success rate for identifying the node, at 74 percent, and the highest complication rate, at 21 percent. Very dilute dye at 1.25 mg per millilitre injected in the subareolar location, meaning under the nipple, had the highest identification rate at 92 percent and the lowest complication rate at 2 percent[1].
That is an unusual result and worth sitting with. Diluting the dye tenfold did not reduce its usefulness. It improved it, while cutting complications by a factor of ten. The concentrated preparation was worse on both axes.
The Complication Itself
The characteristic adverse event is tissue injury at the injection site. Reported presentations range from persistent blue tattooing of the skin, which is cosmetic and eventually fades, through erythema and induration, to full-thickness skin and fat necrosis.
A 2005 case report described a patient who developed skin and fat necrosis of the breast after peritumoral methylene blue injection, progressing to dry gangrene. The authors argued the dye should be replaced with patent blue V, preferably combined with a radioisotope[2]. An earlier series in the American Journal of Surgery documented adverse skin lesions following methylene blue injections for sentinel node localisation[3], and a subsequent review collected further cases alongside the published literature[4].
The mechanism is local rather than systemic. Methylene blue at high concentration is directly toxic to tissue, and when it is deposited superficially in the dermis or in fatty tissue with limited blood supply, it can cause a chemical injury that the tissue does not recover from. Deeper injection into well-perfused tissue, and dilution before injection, both reduce that risk, which is exactly what the concentration data show.
Where This Fits Alongside the Other Clinical Uses
Methylene blue turns up across hospital medicine in ways that look unrelated: an antidote for methemoglobinemia, a vasopressor adjunct in refractory shock, a photosensitiser in photodynamic therapy, and here, a lymphatic tracer. What connects them is not a single biological effect but a set of physical properties. It is intensely coloured, it is water soluble, it moves through tissue predictably, and it absorbs light at a specific wavelength. The lymphatic mapping application uses only the colour.
What This Does Not Tell You About Supplements
It is worth being explicit, because necrosis is an alarming word. This complication comes from injecting a concentrated dye solution directly into breast tissue during surgery. It is a local chemical injury at the site of a needle. Oral methylene blue at supplement doses is absorbed through the gut, diluted in the bloodstream, and never present at anything like that local concentration in skin or fat. The known concerns with oral use are different ones, principally serotonergic drug interactions, haemolysis in G6PD deficiency, and dose-dependent methemoglobinemia at high intake. Injection-site necrosis is not among them.
Frequently Asked Questions
Why use methylene blue instead of the radioactive tracer?
Most centres use both together, because the combination has the highest node identification rate. Where a radioisotope is not available, or where nuclear medicine scheduling is a constraint, a blue dye alone is a workable alternative. Methylene blue is chosen over isosulfan blue in part because it very rarely causes the anaphylactic reactions isosulfan blue is associated with.
How common is the skin necrosis complication?
It depends almost entirely on the preparation. In the largest published comparison, complication rates ranged from 21 percent with full-strength peritumoral injection down to 2 percent with dilute subareolar injection. The severe cases that reach case-report status, with gangrene requiring debridement, are much rarer than that overall figure suggests.
Does the blue staining of the skin go away?
Skin discolouration at the injection site is usually temporary and fades over weeks to months as the dye clears. This is distinct from necrosis, which is tissue death rather than staining and does not resolve on its own.
Can oral methylene blue cause skin necrosis?
There is no basis for that concern. The necrosis reported in this context is a local chemical injury from concentrated dye injected directly into tissue. Oral dosing does not produce comparable local concentrations in skin or subcutaneous fat.
References
- Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer. Am J Surg (2008). PMID 18367146
- Skin and fat necrosis of the breast following methylene blue dye injection for sentinel node biopsy in a patient with breast cancer. Int Semin Surg Oncol (2005). PMID 16313674
- Adverse skin lesions after methylene blue injections for sentinel lymph node localization. Am J Surg (2002). PMID 12383900
- Complications of methylene blue dye in breast surgery: case reports and review of the literature. J Cancer (2010). PMID 21197261
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
